Centiva Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Centiva Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,142	Closed	-$1.73M	–	1841
2023 Q1	$1.73M	Buy	+7,142	New	+$1.95M	0.04%	441

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Centiva Capital's MDGL Position: Q2 2023 in Review

Centiva Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2023, closing a stake of 7,142 shares — an estimated $1.73M sold.

Centiva Capital first reported a position in MDGL in Q1 2023 and held it in 1 quarter. The position peaked at $1.73M in Q1 2023. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

Centiva Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Centiva Capital sold 7,142 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $1.73M.
Centiva Capital first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Centiva Capital's Madrigal Pharmaceuticals position peaked at $1.73M in Q1 2023.
208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.